Tradestie Institutional Equity Comparison Engine

AAPD vs COCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

COCP Overall Edge

COCP Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cocrystal Pharma, Inc. Common Stock (COCP) driven by superior Growth & Margin, Momentum & Technical while AAPD counters with relative strength in Options & Structure. Fundamentally, AAPD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, AAPD sits in UNCLASSIFIED (12th %ile IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AAPD N/M vs COCP N/M Fwd P/E
Growth & Margin Winner COCP
Op Margin N/A vs -3063.6% ยท YoY N/A vs +26.9%
Momentum & Technical Winner COCP
1Y -25.5% vs -3.0% ยท 52W Pos 5% vs 19%
Options & Structure Winner AAPD
UNCLASSIFIED (12th %ile IV) vs UNCLASSIFIED (N/A IV)
AAPD NASDAQ
Direxion Daily AAPL Bear 1X Shares
Institutional Equity
$9.75
+1.35% 1D
Market Cap N/A
1M Return -2.5%
1Y Return -25.46%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 36.0 Fund 49.0 Flow 50.0 Mom 64.0
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AAPD -25.46% COCP -2.96% Spread: +22.5 pp (COCP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AAPD TTM Op. Margin: N/A COCP TTM Op. Margin: -3063.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPD vs COCP. Trailing 12-month operating profitability (AAPD N/A vs COCP -3063.6%) and valuation multiples (AAPD N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AAPD (1) vs COCP (7)
Institutional Metric AAPD COCP Criterion Row Winner
Market Capitalization Scale N/A $19.6M Larger Scale COCP
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +26.9% Higher Growth COCP
Operating Margin (TTM) Profitability N/A -3063.6% Higher Margin COCP
Net Profit Margin Profitability N/A 0.0% Higher Margin COCP
Return on Equity (ROE) Capital Efficiency N/A -311.7% Higher ROE COCP
52-Week Range Position Momentum 5% ($10โ€“$15) 19% ($1โ€“$2) Stronger Trend COCP
Beta / 30D Volatility Risk Regime -0.55ฮฒ ยท 27% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk AAPD
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite COCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AAPD vs COCP Buy Guide
AAPD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live AAPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AAPD nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.